Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Gene Fusions Make Some Pan-Negative Melanomas Sensitive to MEK Inhibitors

By BiotechDaily International staff writers
Posted on 16 Jan 2014
Print article
Image: Scanning electron micrograph of a melanoma cell. BRAF fusion genes in pan-negative melanomas may render them sensitive to MEK inhibitors (Photo courtesy of Vanderbilt University).
Image: Scanning electron micrograph of a melanoma cell. BRAF fusion genes in pan-negative melanomas may render them sensitive to MEK inhibitors (Photo courtesy of Vanderbilt University).
Cancer researchers have identified a class of fusion genes that drive melanoma metastasis in the 35% of these skin cancers that lack the previously known driver mutations.

According to senior author Dr. Jeffrey A. Sosman, professor of medicine at Vanderbilt University (Nashville, TN, USA) "About 35% of melanomas are, as of today, considered "pan-negative,” which means they are devoid of any previously known driver mutations in the genes BRAF, NRAS, KIT, GNAQ, and GNA11."

Dr. Sosman and his colleagues used a targeted next-generation sequencing (NGS) assay (FoundationOne) and targeted RNA sequencing to search for potential drug targets in a series of pan-negative melanoma specimens.

FoundationOne, the first clinical product from the biotech company Foundation Medicine (Cambridge, MA, USA), is the first commercially available targeted sequencing assay utilizing clinical grade next-generation sequencing (NGS) in routine cancer specimens. This test identifies all classes of genomic alterations (including copy number alterations, insertions, deletions, and rearrangements) in hundreds of cancer-related genes. It complements traditional cancer treatment-decision tools and often expands treatment options by matching each patient with targeted therapies that are relevant to the molecular changes in their tumor.

The investigators reported in the December 15, 2013, issue of the journal Clinical Cancer Research that they had found fusions between the bifunctional 3'-phosphoadenosine 5'-phosphosulfate synthetase 1 gene (PAPSS1) and the V-raf murine sarcoma viral oncogene homolog B1 gene (BRAF) and between the BRAF gene and the tripartite motif-containing 24 gene (TRIM24).

Both classes of BRAF fusions activated the MAPK signaling pathway. The investigators treated fusion gene-bearing cells either with the BRAF inhibitor vemurafenib or with trametinib, an inhibitor of MEK, a protein in the MAPK signaling pathway. Results showed that signaling induced by the BRAF fusions was not responsive to vemurafenib but could be inhibited by trametinib, which implied that the fusions could make melanoma cells harboring them sensitive to MEK inhibitors.

"Performing a sophisticated analysis called targeted next-generation sequencing, it appears that about 8% of pan-negative melanomas have BRAF fusions," said Dr. Sosman. "Our results are important because they obviously suggest that there probably are other, as yet unidentified, molecular changes that make these melanomas susceptible to drugs that are available right now."

This study was funded in part by "Stand up to Cancer" (Pasadena, CA, USA), an organization that raises funds to accelerate the pace of cancer research in order to get new therapies to patients quickly and save lives now.

Related Links:
Vanderbilt University
Foundation Medicine
Stand up to Cancer


Print article

Channels

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Lab Technologies

view channel
Image: A three-dimensional printer adapted for stem cell production (Photo courtesy of Nano Dimension).

Israeli Developers Demonstrate Prototype Three-Dimensional Bioprinter

Two Israeli companies have combined efforts in the development of three-dimensional printer technology for the production of stem cells. The three-dimensional print electronics developer Nano Dimension... Read more

Business

view channel

Acquisition to Boost Development of Drugs for Neurogenic Conditions

According to a recent announcement, a privately held biotechnology/drug development company is to be acquired by one of the major pharmaceutical manufacturers. The drug manufacturer Merck & Co. (Kenilworth, NJ, USA) has agreed to pay 500 million USD up front for Afferent Pharmaceuticals (San Mateo, CA, USA) and up... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.